Présentation de l'entreprise
SRx Health Solutions Inc., operating under the ticker SRXH, engages in specialty pharmacy and pet health and wellness businesses across the United States, Taiwan, and international markets. The firm provides pet health and wellness products in various forms, including kibble, canned food, and freeze-dried raw food, catering to a specialized niche within the consumer sector. This entity operates within the Consumer Defensive sector and specifically in the Packaged Foods industry, classifications that suggest a business model potentially insulated from broader economic downturns but subject to specific regulatory and demand dynamics. The company currently maintains a market capitalization of $48.11M and employs 10 individuals to generate annual revenue of $9.34M. These valuation and scale figures indicate a micro-cap status, reflecting a very small enterprise with limited operational breadth that relies on a lean workforce to execute its multi-regional strategy.
Santé financière
The company reported a trailing twelve-month revenue of $9.34M alongside a net income of $-17,253,000, creating a significant disparity that reveals a highly leveraged cost structure where expenses far exceed gross earnings. Despite this negative net income, the entity recorded an EBITDA of $-12,770,000, suggesting that while operational cash generation before interest and taxes is negative, the core business operations still face substantial fixed cost burdens. Regarding cash flow flexibility, the specific figure for free cash flow is not available in the reported data, which implies a need for caution when assessing the company's immediate liquidity generation capabilities independent of financing activities. The company holds $13.06M in cash assets against $21.03M in total debt, resulting in a debt-to-equity ratio of 596.71, which indicates an extremely aggressive leverage position where liabilities significantly outweigh equity. Profitability analysis shows a gross margin of 27.6%, an operating margin of -135.0%, and a profit margin of 0.0%, illustrating that while the cost of goods sold allows for a healthy markup, operating expenses are so high that they not only consume gross profit but also invert the operating margin into deeply negative territory. The current ratio stands at 0.80, signaling that current liabilities exceed current assets and highlighting potential challenges in meeting short-term obligations without refinancing or asset liquidation. Return on equity and return on assets are listed as not available, a condition that precludes a traditional assessment of management's effectiveness in generating returns from shareholders' capital or the asset base due to the company's lack of positive retained earnings and complex capital structure.
Évaluation de la valorisation
Valuation metrics for SRx Health Solutions Inc. present a mixed picture, with the trailing P/E ratio and forward P/E ratio both listed as not available due to the company's consistent net losses over the trailing twelve months. The absence of a positive earnings figure means these traditional multiples cannot be calculated, preventing a direct comparison of current earnings yield against the share price. Instead, the market values the stock at a price-to-book ratio of -1.27, a negative multiple that indicates the market capitalization is below the company's book value, often seen in distressed or turnaround situations where the market assigns a value lower than the net asset position. Alternative valuation measures such as the price-to-sales ratio of 5.15 and an EV/EBITDA of -4.85 suggest that the market is pricing the company based on its revenue generation potential and enterprise value relative to negative earnings, rather than profitability. The stock has experienced significant volatility, trading between a 52-week high of $2.02 and a 52-week low of $0.08. To determine the precise position relative to this range, one must note the wide dispersion between the high and low, where the current share price sits within this broad band of historical trading activity, reflecting the speculative nature of the security. The beta value is not available, which prevents a quantitative assessment of the stock's price volatility relative to the broader market movements.
Growth & Income
Growth metrics for the company are not disclosed in the available data, as the revenue growth year-over-year and earnings growth year-over-year are both listed as not available. This lack of historical growth data makes it impossible to determine whether earnings are growing faster or slower than revenue, as the company has not yet achieved consistent profitability to track these trajectories. Regarding income generation, the dividend yield and payout ratio are both listed as not available, confirming that the company does not distribute dividends to shareholders. Consequently, the firm does not pay a dividend, meaning it retains all earnings—or rather, absorbs all losses—to reinvest into growth initiatives, operational expansion, or debt reduction rather than providing a passive income stream. The overall growth and income profile is characterized by a high-risk, no-dividend structure where the company relies entirely on future operational improvements to generate positive cash flows and shareholder value.